Anthropic’s Claude Science targets scientists with workflows, not a new model

Anthropic has unveiled Claude Science, an AI-powered workbench designed to give researchers a unified environment for computational work, eliminating the friction of switching between databases, pipelines, and scattered tools.

The company is careful to clarify that Claude Science is “not a new AI model” and not a biology-specific upgrade. Instead, it runs the same Claude models available to all users today, including Claude Opus 4.8, with no special access or gating. This builds on the October 2025 launch of Claude for Life Sciences, which enhanced the chatbot’s capabilities in life sciences tasks. Now, Claude Science offers a dedicated workspace for that research.

Announced at an AI for Science briefing on Tuesday, the launch reflects Anthropic’s broader strategy to move beyond being a model provider and instead own the operating layer for specific industries. Just as Claude Code has become the operating layer for software development, Claude Science aims to do the same for scientific research. Anthropic is increasingly betting its growth on vertical, workflow-level products rather than raw model capability, a move that could reshape how it competes and prices against rivals.

Here’s how the platform works: A central AI assistant acts like a project manager for scientists, connecting to over 60 scientific databases and offering prebuilt toolkits for fields such as genomics, protein structure, and chemistry. This assistant can create sub-assistants to delegate tasks or hand work off to a custom “expert” assistant built by the user. A separate fact-checker AI then verifies citations and calculations before anything is published. This step is critical, as AI-assisted writing has led to fabricated citations and unverifiable stats in papers, though the fact-checker still relies on the same underlying model rather than an independent source of truth.

Claude Science also prioritizes reproducibility. The workbench can generate figures like 3D protein structures and chemistry diagrams alongside the code that produced them. Each figure includes the exact code, environment, a plain-language description of its creation, and the full message history. This saves scientists time by letting them edit figures in plain language, prompting the agent to update its own code.

Another time-saver: Claude Science can run on the lab’s own infrastructure, keeping data on-site rather than sending it to Anthropic’s servers.

Early adopters are already seeing results. Allen Institute neuroscientist Jérôme Lecoq used the tool to build a multi-agent computational review pipeline. Stephen Francis’s group at the UCSF Brain Tumor Center used Claude Science to accelerate comprehensive germline analysis of glioma from months to a fraction of the time, with results independently validated.

This launch comes months after OpenAI took a different approach with GPT-Rosalind, a specialized model fine-tuned for biological reasoning, released in April. The key difference isn’t just about whether a specialized model is necessary but also about access and speed. Rosalind launched as a research preview limited to qualified U. S. enterprise customers, gated behind a safety review, with early access granted to partners like Amgen, Allen Institute, Moderna, Thermo Fisher, and Novo Nordisk.

Then there’s Google DeepMind, playing a different game entirely. DeepMind owns foundational science models like AlphaFold and AlphaGenome, which competitors can only call as tools. Its Gemini for Science platform bundles these models with over 30 life science databases into one skill set.

The result: three distinct distribution strategies are vying for the same scientific research market. Anthropic goes wide with broad subscription access, OpenAI goes narrow with enterprise gating, and Google leans on proprietary models no one else has. How this plays out could signal how AI vendors compete in other specialized verticals like law, finance, and engineering.

Claude Science is available in beta to anyone on Pro, Max, Team, and Enterprise subscriptions. Anthropic has named Novo Nordisk and the Allen Institute as customer case studies, indicating that pharma organizations are already working with multiple AI vendors.

Additionally, Anthropic will support up to 50 Claude Science projects with up to $30,000 in credits. The company is seeking postdoctoral and graduate projects spanning domains and exploring the boundaries of science, with an early focus on biomedical research. Applications are open through July 15, 2026, with award notifications by July 31. Projects will run from September 1 to December 1, 2026.